AMDL Launches Expanded Distribution With 4th Round of Agreements Valued at $6.79 Million Annually for New Health & Beauty Produc
November 07 2007 - 5:00AM
PR Newswire (US)
TUSTIN, Calif., Nov. 7 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), with operations in Shenzhen, Jiangxi and Jilin, China,
through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI),
which is an international biopharma company that engages in the
development, manufacture and marketing of proprietary
pharmaceutical and diagnostic products, announced today that JPI's
subsidiary JJB has signed the fourth round of regional distribution
agreements for its new anti-aging and skin care injectable product
under the brand name "Goodnak." This initial product is the first
in a new line of anti-aging & skin care products currently
under development by JJB. JJB has signed three new Central Region
exclusive, one-year renewable Distribution and Agency Agreements
that were signed between Jade Pharma's subsidiary JJB and Henan
Yinji Bio-chemistry Co., Ltd. ("HYB"), Chengdu Fairyland Cosmetics
Co., Ltd. and ("CFC"), Guizhou Camry Beauty Technology Co., Ltd.
("GCB"). These agreements cover the key cities in Henan, Sichuan
and Guizhou Provinces that have a combined population of
approximately 134.4 million people. These two separate agreements
in combination, require these new distributors to purchase a
minimum of US$6,790,944 of JJB's new HPH product during the
one-year period of the contracts and a minimum initial order of
US$4,061,250. Frank Zheng, managing director of JPI, said this
fourth round of additional distribution agreements, coupled with
the previously announced agreements, puts the Company on the path
to building sales of Goodnak by as much as $24 million over the
next 12 months. Gary Dreher, CEO of AMDL said the Company expects
to further update the market on its expansion plans in the coming
weeks. About Goodnak: Goodnak is a high quality injectable
anti-aging & skin care product that contains an amalgam of
various therapeutic elements including human placental
histosolution ("HPH"). JPI has begun selling Goodnak, in August,
through wholesale distribution channels that service high-end
beauty salon and plastic surgery hospitals and or medical
cosmetology institutions. Goodnak product information is available
on Jade Pharma's product specific website:
http://www.jade-amdl.com/. About JPI: Jade Pharmaceutical through
its subsidiaries JJB & YYB has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiary, Jade currently manufactures large volume
injectable fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements: This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 VoiceMail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Mr. Paul Knopick, Investor Relations of AMDL, Inc.,
+1-949-707-5365, VoiceMail, +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024